One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-72, 2008. ,
DOI : 10.1200/JCO.2007.15.4377
Pancreatic neuroendocrine tumors: a review, Future Oncology, vol.28, issue.7, pp.853-64, 2015. ,
DOI : 10.1097/COC.0b013e31815e4557
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors, Gastroenterology, vol.135, issue.5, pp.1469-92, 2008. ,
DOI : 10.1053/j.gastro.2008.05.047
URL : http://europepmc.org/articles/pmc2612755?pdf=render
Emerging therapies for pancreas neuroendocrine cancers, Chinese Clin Oncol, vol.2, p.23, 2013. ,
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system, Annals of Oncology, vol.15, issue.6, pp.966-73, 2004. ,
DOI : 10.1093/annonc/mdh216
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.371, issue.3, pp.224-257, 2014. ,
DOI : 10.1056/NEJMoa1316158
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, Journal of Clinical Oncology, vol.27, issue.28, pp.4656-63, 2009. ,
DOI : 10.1200/JCO.2009.22.8510
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, pp.1199-203, 2011. ,
DOI : 10.1056/NEJMoa1001671
URL : http://europepmc.org/articles/pmc3144496?pdf=render
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway, Journal of Clinical Oncology, vol.28, issue.2, pp.245-55, 2010. ,
DOI : 10.1200/JCO.2008.21.5988
Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors, Anticancer Res, vol.30, pp.5063-5070, 2010. ,
mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases, Hepatogastroenterology, vol.58, issue.112, pp.2140-2143, 2011. ,
DOI : 10.5754/hge11212
Expression of PTEN and mTOR in pancreatic neuroendocrine tumors, Tumor Biology, vol.256, issue.5, pp.2871-2880, 2013. ,
DOI : 10.1097/SLA.0b013e31824e6108
The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells, Neuroendocrinology, vol.25, issue.1, pp.54-60, 2007. ,
DOI : 10.1074/jbc.273.23.14424
Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-537, 2011. ,
DOI : 10.1056/NEJMoa1009290
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt, Cancer Research, vol.66, issue.3, pp.1500-1508, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-2925
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, Journal of Clinical Investigation, vol.118, pp.3065-74, 2008. ,
DOI : 10.1172/JCI34739DS1
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway, The EMBO Journal, vol.62, issue.17, pp.3943-54, 2006. ,
DOI : 10.1128/MCB.22.12.4062-4072.2002
Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression, Cancer Research, vol.66, issue.3, pp.1576-82, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-1189
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial, Journal of Clinical Oncology, vol.28, issue.1, pp.69-76, 2010. ,
DOI : 10.1200/JCO.2009.24.2669
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures, Endocrine Related Cancer, vol.364, issue.6, pp.691-704, 2014. ,
DOI : 10.1056/NEJMoa1009290
URL : https://hal.archives-ouvertes.fr/hal-01176951
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors, Clinical Cancer Research, vol.23, issue.2, pp.600-609, 2017. ,
DOI : 10.1158/1078-0432.CCR-16-1113
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors, Clinical Cancer Research, vol.18, issue.6, pp.1777-89, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2123
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma, Cancer Chemotherapy and Pharmacology, vol.378, issue.3, pp.999-1007, 2014. ,
DOI : 10.1016/S0140-6736(11)61613-9
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, openlabel , two-way crossover study of healthy volunteers, Clin Pharmacol, vol.7, pp.11-18, 2015. ,
Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients, Pancreas, vol.37, issue.1, pp.94-100, 2008. ,
DOI : 10.1097/MPA.0b013e31816907ab
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study, Cancer Chemotherapy and Pharmacology, vol.29, issue.Suppl 1, pp.387-95, 2013. ,
DOI : 10.1200/JCO.2010.33.2056
The gsp Oncogene Disrupts Ras/ERK-Dependent Prolactin Gene Regulation in gsp Inducible Somatotroph Cell Line, Endocrinology, vol.152, issue.4, pp.1234-1277, 2011. ,
DOI : 10.1210/en.2010-1077
URL : https://hal.archives-ouvertes.fr/hal-00625462
Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro, Endocrine Related Cancer, vol.16, issue.3, pp.1017-1044, 2009. ,
DOI : 10.1677/ERC-08-0269
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.2, pp.968-76, 2010. ,
DOI : 10.1210/jc.2009-1641
The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells, Cancer Research, vol.70, issue.2, pp.666-74, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-2951
Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line, Neuroendocrinology, vol.86, issue.3, pp.168-81, 2008. ,
DOI : 10.1073/pnas.91.6.2315
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors, Endocrine Related Cancer, vol.15, issue.1, pp.257-66, 2008. ,
DOI : 10.1677/ERC-07-0202
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies, Expert Opinion on Pharmacotherapy, vol.11, issue.7, pp.2191-205, 2016. ,
DOI : 10.1007/s40265-016-0539-6
Glycemic Control in Patients with Insulinoma Treated with Everolimus, New England Journal of Medicine, vol.360, issue.2, pp.195-202, 2009. ,
DOI : 10.1056/NEJMc0806740
Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues, The Oncologist, vol.16, issue.6, pp.783-790, 2011. ,
DOI : 10.1634/theoncologist.2010-0222
Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia, European Journal of Endocrinology, vol.23, issue.8, pp.665-74, 2013. ,
DOI : 10.1093/annonc/mds115
Everolimus Dramatically Improves Glycemic Control in Unresectable Metastatic Insulinoma: A Case Report, Japanese Journal of Clinical Oncology, vol.335, issue.6076, pp.186-90, 2014. ,
DOI : 10.1126/science.1215135
Symptomatic Control of Neuroendocrine Tumours with Everolimus, Hormones and Cancer, vol.22, issue.17, pp.254-263, 2015. ,
DOI : 10.1200/JCO.2004.03.025
PI3K p110??/Akt Signaling Negatively Regulates Secretion of the Intestinal Peptide Neurotensin Through Interference of Granule Transport, Molecular Endocrinology, vol.26, issue.8, pp.1380-93, 2012. ,
DOI : 10.1210/me.2012-1024
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors, Clinical Cancer Research, vol.20, issue.5, pp.1212-1234, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-1897
Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation, PLoS ONE, vol.246, issue.11, p.81111, 2013. ,
DOI : 10.1371/journal.pone.0081111.t001
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives, Future Oncology, vol.2, issue.11, pp.1809-1837, 2015. ,
DOI : 10.1200/JCO.2011.40.9631
Cellular survival: a play in three Akts, Genes & Development, vol.13, issue.22, pp.2905-2932, 1999. ,
DOI : 10.1101/gad.13.22.2905
Functions and regulation of the 70kDa ribosomal S6 kinases, The International Journal of Biochemistry & Cell Biology, vol.43, issue.1, pp.47-59, 2011. ,
DOI : 10.1016/j.biocel.2010.09.018
Compensatory activation of Akt in response to mTOR and Raf inhibitors ??? A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease, Cancer Letters, vol.295, issue.1, pp.100-109, 2010. ,
DOI : 10.1016/j.canlet.2010.02.018
Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor, Molecular and Cellular Endocrinology, vol.350, issue.1, pp.99-106, 2012. ,
DOI : 10.1016/j.mce.2011.11.024
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study, Endocrine Related Cancer, vol.92, issue.3, pp.657-66, 2012. ,
DOI : 10.1093/jnci/92.3.205
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids, Endocrine Related Cancer, vol.17, issue.3, pp.719-748, 2010. ,
DOI : 10.1677/ERC-10-0097
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study, Journal of Clinical Oncology, vol.26, issue.26, pp.4311-4319, 2008. ,
DOI : 10.1200/JCO.2008.16.7858
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications, Neuroendocrinology, vol.250, issue.1, pp.45-56, 2013. ,
DOI : 10.1148/radiol.2501080291
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors, Clin Cancer Res, vol.9, pp.1469-73, 2003. ,
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours, Histopathology, vol.10, issue.2, pp.133-141, 1998. ,
DOI : 10.1016/0167-4889(94)90016-7
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors, Cancer, vol.23, issue.8, pp.1478-86, 2007. ,
DOI : 10.1016/S0002-9440(10)65289-3
Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients, Cancer Investigation, vol.18, issue.1, pp.8-12, 2001. ,
DOI : 10.1016/0167-0115(93)90356-D
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells, International Journal of Cancer, vol.5, issue.4, pp.545-50, 2001. ,
DOI : 10.1074/jbc.273.12.7099
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nature Medicine, vol.11, issue.2, pp.128-163, 2002. ,
DOI : 10.1006/cyto.1998.0426
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion, Endocrine Related Cancer, vol.14, issue.1, pp.91-102, 2007. ,
DOI : 10.1677/ERC-06-0026
VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway, Neuroendocrinology, vol.91, issue.3, pp.268-78, 2010. ,
DOI : 10.1159/000289569
URL : https://hal.archives-ouvertes.fr/hal-00475083
Development of Targeted Somatostatin-Based Antiangiogenic Therapy: A Review and Future Perspectives, Cancer Biotherapy & Radiopharmaceuticals, vol.18, issue.4, pp.601-610, 2003. ,
DOI : 10.1089/108497803322287691
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin, Cancer Cell, vol.10, issue.2, pp.159-70, 2006. ,
DOI : 10.1016/j.ccr.2006.07.003
URL : https://doi.org/10.1016/j.ccr.2006.07.003
Effects of Somatostatin and Octreotide on the Interactions between Neoplastic Gastroenteropancreatic Endocrine Cells and Endothelial Cells: A Comparison between in vitro and in vivo Properties, Neuroendocrinology, vol.15, issue.3, pp.200-208, 2011. ,
DOI : 10.1158/1078-0432.CCR-08-2346
URL : https://hal.archives-ouvertes.fr/hal-00710320
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.501-514, 2011. ,
DOI : 10.1056/NEJMoa1003825
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors, Endocrine-Related Cancer, vol.60, issue.11, pp.883-91, 2016. ,
DOI : 10.1530/ERC-15-0413
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms, Best Practice & Research Clinical Endocrinology & Metabolism, vol.30, issue.1, pp.59-77, 2016. ,
DOI : 10.1016/j.beem.2016.01.002
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours, Endocrine Related Cancer, vol.13, issue.1, pp.135-184, 2006. ,
DOI : 10.1677/erc.1.01090
Rap1/B-Raf Signaling Is Activated in Neuroendocrine Tumors of the Digestive Tract and Raf Kinase Inhibition Constitutes a Putative Therapeutic Target, Neuroendocrinology, vol.4, issue.1, pp.45-53, 2007. ,
DOI : 10.1210/me.15.9.1559
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition, Oncotarget, vol.5, issue.14, pp.5381-91, 2014. ,
DOI : 10.18632/oncotarget.2111
Hormonal Regulation of Prolactin Release by Human Prolactinoma Cells Cultured in Serum-Free Conditions, Hormone Research, vol.22, issue.3, pp.153-63, 1985. ,
DOI : 10.1159/000180089
Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis, European Journal of Endocrinology, vol.20, issue.1, pp.533-574, 2013. ,
DOI : 10.1002/humu.10092
URL : https://hal.archives-ouvertes.fr/hal-00933803
Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas, J Clin Endocrinol Metab, vol.86, pp.140-145, 2001. ,